JucaBio, LLC was established to build biotech companies around promising, novel therapeutics in areas of high unmet need. 

Each subsidiary of JucaBio will contain a single therapeutic. Our team will develop this therapeutic to a value inflection point, to which it will be sold or acquired for the purposes of commercialization. JucaBio’s model efficiently identifies and acquires novel therapeutics that are often left “on the shelf” when large pharma and biotech change strategic direction. Our team has a deep expertise in clinical development, venture capital, and venture creation – with a proven track record of successful exits.